Research ExplorerPublicationsPatients with IgA nephropathy exhibit high systemic PDGF-DD ...

Patients with IgA nephropathy exhibit high systemic PDGF-DD levels

Standard

Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. / Boor, Peter; Eitner, Frank; Cohen, Clemens D; Lindenmeyer, Maja T; Mertens, Peter R; Ostendorf, Tammo; Floege, Jürgen; ERCB-Consortium.

In: NEPHROL DIAL TRANSPL, Vol. 24, No. 9, 09.2009, p. 2755-62.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Boor, P, Eitner, F, Cohen, CD, Lindenmeyer, MT, Mertens, PR, Ostendorf, T, Floege, J & ERCB-Consortium 2009, 'Patients with IgA nephropathy exhibit high systemic PDGF-DD levels', NEPHROL DIAL TRANSPL, vol. 24, no. 9, pp. 2755-62. https://doi.org/10.1093/ndt/gfp152

APA

Boor, P., Eitner, F., Cohen, C. D., Lindenmeyer, M. T., Mertens, P. R., Ostendorf, T., Floege, J., & ERCB-Consortium (2009). Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. NEPHROL DIAL TRANSPL, 24(9), 2755-62. https://doi.org/10.1093/ndt/gfp152

Vancouver

Boor P, Eitner F, Cohen CD, Lindenmeyer MT, Mertens PR, Ostendorf T et al. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. NEPHROL DIAL TRANSPL. 2009 Sep;24(9):2755-62. https://doi.org/10.1093/ndt/gfp152

Bibtex

@article{bab336b24c0f47708e0207e89b2c9310,
title = "Patients with IgA nephropathy exhibit high systemic PDGF-DD levels",
abstract = "BACKGROUND: Platelet-derived growth factor (PDGF) is a central mediator of mesangioproliferative glomerulonephritis (GN). In experimental mesangioproliferative GN, PDGF-DD serum levels, unlike PDGF-BB, increased up to 1000-fold.METHODS: We assessed disease activity in 72 patients with GN, established a novel PDGF-D ELISA and then determined their PDGF-DD levels. In parallel, we studied renal PDGF-DD mRNA expression by RT-PCR.RESULTS: PDGF-DD serum levels in patients with IgA nephropathy (IgAN) were significantly higher (1.67 +/- 0.45 ng/ml) and in patients with lupus nephritis significantly lower (0.66 +/- 0.86 ng/ml) compared to healthy controls (1.17 +/- 0.46 ng/ml), while patients with focal segmental glomerulosclerosis, membranous GN and ANCA-positive vasculitis did not differ from controls. The subgroup of IgAN patients with elevated PDGF-DD levels (27% of samples) did not differ in their clinical features from those with normal PDGF-DD levels. In IgAN patients with repetitive PDGF-DD determinations, most exhibited only minor fluctuations of serum levels over time. Intrarenal PDGF-DD mRNA expression did not differ between controls and patients, suggesting an extrarenal source of the elevated PDGF-DD in IgAN.CONCLUSIONS: Serum PDGF-DD levels were specifically elevated in patients with IgAN, in particular in those with early disease, i.e. preserved renal function. Our data support the rationale for anti-PDGF-DD therapy in mesangioproliferative GN.",
keywords = "Adolescent, Adult, Aged, Antibodies, Antineutrophil Cytoplasmic, Becaplermin, Biomarkers, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Glomerulonephritis, IGA, Glomerulonephritis, Membranoproliferative, Glomerulonephritis, Membranous, Glomerulosclerosis, Focal Segmental, Humans, Kidney, Lupus Nephritis, Male, Middle Aged, Platelet-Derived Growth Factor, Proteinuria, Proto-Oncogene Proteins c-sis, RNA, Messenger, Vasculitis, Young Adult, Journal Article, Research Support, Non-U.S. Gov't",
author = "Peter Boor and Frank Eitner and Cohen, {Clemens D} and Lindenmeyer, {Maja T} and Mertens, {Peter R} and Tammo Ostendorf and J{\"u}rgen Floege and ERCB-Consortium",
year = "2009",
month = sep,
doi = "10.1093/ndt/gfp152",
language = "English",
volume = "24",
pages = "2755--62",
journal = "NEPHROL DIAL TRANSPL",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Patients with IgA nephropathy exhibit high systemic PDGF-DD levels

AU - Boor, Peter

AU - Eitner, Frank

AU - Cohen, Clemens D

AU - Lindenmeyer, Maja T

AU - Mertens, Peter R

AU - Ostendorf, Tammo

AU - Floege, Jürgen

AU - ERCB-Consortium

PY - 2009/9

Y1 - 2009/9

N2 - BACKGROUND: Platelet-derived growth factor (PDGF) is a central mediator of mesangioproliferative glomerulonephritis (GN). In experimental mesangioproliferative GN, PDGF-DD serum levels, unlike PDGF-BB, increased up to 1000-fold.METHODS: We assessed disease activity in 72 patients with GN, established a novel PDGF-D ELISA and then determined their PDGF-DD levels. In parallel, we studied renal PDGF-DD mRNA expression by RT-PCR.RESULTS: PDGF-DD serum levels in patients with IgA nephropathy (IgAN) were significantly higher (1.67 +/- 0.45 ng/ml) and in patients with lupus nephritis significantly lower (0.66 +/- 0.86 ng/ml) compared to healthy controls (1.17 +/- 0.46 ng/ml), while patients with focal segmental glomerulosclerosis, membranous GN and ANCA-positive vasculitis did not differ from controls. The subgroup of IgAN patients with elevated PDGF-DD levels (27% of samples) did not differ in their clinical features from those with normal PDGF-DD levels. In IgAN patients with repetitive PDGF-DD determinations, most exhibited only minor fluctuations of serum levels over time. Intrarenal PDGF-DD mRNA expression did not differ between controls and patients, suggesting an extrarenal source of the elevated PDGF-DD in IgAN.CONCLUSIONS: Serum PDGF-DD levels were specifically elevated in patients with IgAN, in particular in those with early disease, i.e. preserved renal function. Our data support the rationale for anti-PDGF-DD therapy in mesangioproliferative GN.

AB - BACKGROUND: Platelet-derived growth factor (PDGF) is a central mediator of mesangioproliferative glomerulonephritis (GN). In experimental mesangioproliferative GN, PDGF-DD serum levels, unlike PDGF-BB, increased up to 1000-fold.METHODS: We assessed disease activity in 72 patients with GN, established a novel PDGF-D ELISA and then determined their PDGF-DD levels. In parallel, we studied renal PDGF-DD mRNA expression by RT-PCR.RESULTS: PDGF-DD serum levels in patients with IgA nephropathy (IgAN) were significantly higher (1.67 +/- 0.45 ng/ml) and in patients with lupus nephritis significantly lower (0.66 +/- 0.86 ng/ml) compared to healthy controls (1.17 +/- 0.46 ng/ml), while patients with focal segmental glomerulosclerosis, membranous GN and ANCA-positive vasculitis did not differ from controls. The subgroup of IgAN patients with elevated PDGF-DD levels (27% of samples) did not differ in their clinical features from those with normal PDGF-DD levels. In IgAN patients with repetitive PDGF-DD determinations, most exhibited only minor fluctuations of serum levels over time. Intrarenal PDGF-DD mRNA expression did not differ between controls and patients, suggesting an extrarenal source of the elevated PDGF-DD in IgAN.CONCLUSIONS: Serum PDGF-DD levels were specifically elevated in patients with IgAN, in particular in those with early disease, i.e. preserved renal function. Our data support the rationale for anti-PDGF-DD therapy in mesangioproliferative GN.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antibodies, Antineutrophil Cytoplasmic

KW - Becaplermin

KW - Biomarkers

KW - Case-Control Studies

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Glomerulonephritis, IGA

KW - Glomerulonephritis, Membranoproliferative

KW - Glomerulonephritis, Membranous

KW - Glomerulosclerosis, Focal Segmental

KW - Humans

KW - Kidney

KW - Lupus Nephritis

KW - Male

KW - Middle Aged

KW - Platelet-Derived Growth Factor

KW - Proteinuria

KW - Proto-Oncogene Proteins c-sis

KW - RNA, Messenger

KW - Vasculitis

KW - Young Adult

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1093/ndt/gfp152

DO - 10.1093/ndt/gfp152

M3 - SCORING: Journal article

C2 - 19357108

VL - 24

SP - 2755

EP - 2762

JO - NEPHROL DIAL TRANSPL

JF - NEPHROL DIAL TRANSPL

SN - 0931-0509

IS - 9

ER -